ArticleClinical and experimental nephrology2026
Peroxidasin expression patterns predict fibrosis and kidney function decline in IgA nephropathy.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxidasin (PXDN), a heme-containing peroxidase involved in basement membrane assembly, has been increasingly implicated in fibrotic processes, yet its role in kidney disease remains unclear. We therefore characterized PXDN expression in kidney biopsies from patients with IgA nephropathy (IgAN), a leading cause of CKD, and assessed its association with fibrosis. Immunofluorescence demonstrated widespread PXDN expression across renal compartments, with predominant localization in distal tubules, consistent with healthy tissue. In contrast, PXDN expression was reduced in proximal tubules, including non-atrophic segments, and markedly increased in the fibrotic interstitium. PXDN strongly correlated with collagen III deposition in sclerotic glomeruli and fibrotic interstitium, but not with collagen IV. Clinically, patients with impaired kidney function (eGFR < 60 ml/min/1.73 m²) exhibited higher PXDN expression in glomeruli, proximal tubules, and fibrotic interstitium, with glomerular PXDN inversely correlating with eGFR. These findings reveal compartment-specific alterations in PXDN expression in IgAN, associated with interstitial fibrosis, collagen III deposition, and declining kidney function. PXDN may participate in fibrotic remodeling processes and represents a potential therapeutic target, warranting further investigation in CKD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.